Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc.

PMVP

0.00

Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ: PMVP) with a Outperform and lowers the price target from $6 to $5.